Meta-analysis of Shengyang Yiwei Decoction as The Main Intervention in The Treatment of Diarrhea-Predominant Irritable Bowel Syndrome

Abstract

OBJECTIVE: To investigate the efficacy and safety of Shengyang Yiwei Decoction as the main intervention in the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D), and to provide evidence for its clinical application. METHODS: Randomized controlled trials (RCTs) of Shengyang Yiwei Decoction in The treatment of IBS-D were searched from CNKI, Wanfang database, PubMed, The Cochrane Library and VIP database from the establishment of these databases to June 10, 2020. The Cochrane risk bias tool in the Cochrane manual was used to evaluate the literature quality. Meta-analysis was performed using RevMan5.3 software. Results: A total of 16 RCTs were included, involving 1244 patients. Meta-analysis results showed that: Total effective rate (N =1204, OR=3.38, 95%CI [2.43, 4.71], P